Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Carcinoma, Small Cell 1

Interventions

atezolizumab 2Trastuzumab 2Magnetic Resonance Spectroscopy 2vandetanib 1tivozanib 1tipifarnib 1temsirolimus 1romidepsin 1pembrolizumab 1pasireotide 1methyl hydroxyethyl cellulose 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entinostat 1Walking 1Vinorelbine 1Suramin 1Standard of Care 1Specimen Handling 1Sirolimus 1Ritonavir 1Respiratory Therapy 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × PT-100 dipeptide × Endocrine × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡